Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faith Davies

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Blood Advances|July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trialsCharles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
Blood|September 13, 2003
Identification of genes modulated in multiple myeloma using genetically identical twin samplesNikhil C Munshi, Teru Hideshima, Daniel Carrasco, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 14, 2023
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review StudyLucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, et al.
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasiaBob Löwenberg, Gareth Morgan, Gert J Ossenkoppele, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Cancer Research|September 5, 2002
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentBoris Lin, Klaus Podar, Deepak Gupta, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Blood Advances|July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trialsCharles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
Blood|September 13, 2003
Identification of genes modulated in multiple myeloma using genetically identical twin samplesNikhil C Munshi, Teru Hideshima, Daniel Carrasco, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 14, 2023
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review StudyLucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, et al.
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasiaBob Löwenberg, Gareth Morgan, Gert J Ossenkoppele, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Cancer Research|September 5, 2002
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentBoris Lin, Klaus Podar, Deepak Gupta, et al.
Pageof 6